Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.36 |
| ▸ | TYK2 | P29597 | 6/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099143 | 0.89 | F10 (0.36) | F10TYK2GPR52ROCK1 | |
| SCHEMBL26098815 | 0.89 | F10 (0.35) | F10TYK2GPR52ROCK1 | |
| SCHEMBL26102480 | 0.85 | TYK2 (0.36) | F10TYK2GPR52ROCK1 | |
| SCHEMBL30392380 | 0.85 | TYK2 (0.40) | F10TYK2 | |
| SCHEMBL26100095 | 0.85 | TYK2 (0.40) | F10TYK2 | |
| SCHEMBL26098580 | 0.85 | NAPEPLD (0.35) | F10TYK2ROCK1NAPEPLD | |
| SCHEMBL30391637 | 0.85 | TYK2 (0.33) | F10TYK2ROCK1 | |
| SCHEMBL26099972 | 0.85 | TYK2 (0.33) | F10TYK2ROCK1 | |
| SCHEMBL31161292 | 0.83 | TYK2 (0.34) | F10TYK2GPR52ROCK1 | |
| SCHEMBL26099627 | 0.83 | TP53 (0.38) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | F10 3484/4885TYK2 1/4885GPR52 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.